ClinicalTrials.gg
Not yet recruitingNCT06328725Updated Mar 25, 2024

Evaluate the Efficacy and Safety of EN001 in Patients With Duchenne Muscular Dystrophy

A Phase 1/2 interventional study of EN001 in Duchenne Muscular Dystrophy, sponsored by ENCell. Not yet recruiting at 2 sites in Korea, Republic of. Open to male participants aged 6 Years to 11 Years. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by ENCell · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
6 Years to 11 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of — 3 open to participants now, 9 under way, 3 of them phase 3. Muscular Dystrophy, Duchenne · Korea, Republic of.

Planned enrollment
12th of 20
88 · median 106
Started
2024
with 4 others
Phase 1/2
3 of 23
1 open now
Registered
21st of 23
by date
Lead sponsor
2 of 23
ENCell

Among the 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of, this one is the 12th largest by planned enrollment of the 20 interventional ones that give a count, is one of 5 that started in 2024, is one of 3 in phase 1/2, and was the 21st registered.

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 106 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

3 of the 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 6 Years to 11 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Dystrophy, Duchenne with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 1/2 Trial to Evaluate the Efficacy and Safety of EN001 in Patients with Duchenne Muscular Dystrophy

Read the detailed description

This clinical trial is a multi-center study conducted in two phases: Phase 1 and Phase 2. Phase 1 follows a 3+3 dose-escalation design to assess the safety, efficacy, and tolerability of EN001, an investigational product. Phase 2 evaluates the efficacy and safety of EN001 at the recommended phase 2 dose (RP2D), as determined in Phase 1, compared to a placebo.

Phase 1 is designed using the traditional 3+3 dose-escalation method to determine the maximum tolerated dose (MTD) and establish the RP2D. Dose escalation continues until the MTD is identified, which must be within the maximum planned dose (MPD) of 2.5 x 10\^6 cells/kg (Cohort 2) or lower. The MTD is defined as the highest dose at which the incidence rate of dose-limiting toxicity (DLT) is less than 33%. To determine the MTD, 3-6 subjects are enrolled in each dose cohort. They receive EN001 every 6 weeks for 3 cycles, with DLTs evaluated up to the 2-week time point (Visit 7).

The Safety Review Committee (SRC) consists of the coordinating Investigator, the responsible trial monitor for subjects enrolled in cohorts requiring safety review, and the sponsor. These members participate as committee members. At the conclusion of each cohort-defined as the endpoint of the DLT assessment for the last subject in that cohort-they comprehensively review the safety data for EN001. The committee makes decisions related to dose adjustments, whether to increase or decrease the dose, and ultimately determines the RP2D.

Phase 2 clinical trials are randomized, double-blind, placebo-controlled clinical trials.

In phase 2, eligible subjects will be randomly assigned to the test group (recommended phase 2 dose (RP2D) of EN001) or the control group (placebo of EN001) in a 1:1 ratio. Efficacy and safety will be evaluated up to 48 weeks after EN001 administration compared to placebo.

In addition, test subjects participating in phase 1 and phase 2 will be followed up for safety and effectiveness for 5 years from the time of EN001 administration according to the long-term follow-up protocol.

03

Conditions studied

  • Duchenne Muscular Dystrophy
04

Who can participate

Ages eligible
6 Years to 11 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males aged between 6 and 11 years at the time of providing written consent.
  2. Individuals exhibiting phenotypic signs of Duchenne Muscular Dystrophy (DMD), such as lower limb muscle weakness, a duck walk, or Gower's sign, and who are diagnosed with DMD following confirmation of a dystrophin gene mutation through genetic testing.
  3. Participants who meet the Time to Stand Test (TTSTAND) criteria without the use of assistive devices or help from others during screening and baseline assessments:

    • Phase 1: Capable of completing the TTSTAND evaluation.
    • Phase 2: TTSTAND time of 10 seconds or less.
  4. Participants with a 6-Minute Walk Test (6MWT) result of 75 meters or more at screening and baseline.
  5. Individuals who meet the following laboratory test criteria at the time of screening and baseline:

    • ≥10 g/dL
    • ≥50,000/μL
    • Serum albumin ≥2.5 g/dL
    • Gamma glutamyl transferase (γ-GT) and total ≤ (ULN)
    • Serum creatinine ≤ 1.5 x ULN
  6. Participants who have been on a stable dose of for at least 12 weeks prior to screening, with treatment maintained. Dosage adjustments for body weight changes are allowed.
  7. Individuals who, along with their representatives when applicable, have voluntarily agreed in writing to participate in this clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with confirmed comorbidities at the time of screening:

    • (LVEF) below 50%, as determined by echocardiography
    • Percent predicted forced vital capacity (FVC%) less than 35%
    • Positive for surface antigen (HBsAg). However, individuals undergoing interferon or antiviral treatment can register
    • Positive for virus antibody (HCV Ab). Registration is possible if the HCV ribonucleic acid (RNA) test result is negative
    • Positive for (HIV) antibody
    • Comorbidities that are uncontrollable or require treatment that could affect the safety and efficacy evaluation of this clinical trial, based on the investigator's judgment
  2. Individuals with confirmed treatment history at the time of screening:

    • Administration of cell therapy or gene therapy throughout life
    • Administer antisense oligonucleotide (e.g., exon skipping treatment) or stop- codon readthrough treatment (e.g., aminoglycoside, ataluren) within 24 weeks before screening.
    • Administration of the following medications within 12 weeks before screening: Idebenone, Resveratrol, Adenosine triphosphate
    • Administration of the following medications within 12 weeks before screening. However, registration is possible if the drug is being administered at a stable dose for at least 12 weeks before screening and the dose is expected to remain unchanged during the clinical trial period. Angiotensin-converting enzyme (ACE) inhibitor Angiotensin II receptor blocker (ARB) Beta-blocker Aldosterone antagonist Ivabradine Sacubitril Growth hormone Anabolic steroids
    • Major surgery within 12 weeks before screening or expected major surgery during the clinical trial period.
    • Use of other products (or medical devices) within 4 weeks before screening.
    • Use of systemic other than systemic .
  3. Individuals requiring mechanical ventilation during the day.
  4. Persons with to the components of the clinical investigational products.
  5. Individuals unwilling to use appropriate from the date of written consent to the termination visit:

    • Appropriate contraceptive methods are as follows, and use more than one method.

      • The use of hormonal contraceptives by the partner
      • Implantation of an intrauterine device or system in your partner
      • Sterilization or surgical procedures for you or your partner
  6. Others who, in the investigator's discretion, are not willing or able to comply with the clinical trial procedures.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Phase 1 - Cohort 1

    EN001 5.0x10\^5 cells/kg

    Drug: EN001

  • Active comparator
    Phase 1 - Cohort 2

    EN001 2.5x10\^6 cells/kg

    Drug: EN001

  • Placebo comparator
    Phase 2 - Experimental Group

    The recommended phase 2 dose (RP2D) of EN001

    Drug: EN001

  • Placebo comparator
    Phase 2 - Control Group

    EN001 placebo

    Drug: EN001

Interventions

  • DrugEN001

    Phase 1 * Cohort 1: EN001 5.0x10\^5 cells/kg administered intravenously (IV) 3 times at 6 week intervals. * Cohort 2: EN001 2.5x10\^6 cells/kg administered intravenously (IV) 3 times at 6 week intervals. Phase 2 * Experimental Group: The recommended phase 2 dose (RP2D) of EN001 is administered intravenously (IV) three times at six-week intervals. * Control Group: EN001 placebo is administered intravenously (IV) three times at six-week intervals.

    Also known as: EN001(allogenic early-passage mesenchymal stem cells derived from Wharton's jelly (WJ-MSCs) )

06

What researchers measure

Primary outcomes

  1. <Phase 1> Adverse drug reactions related to dose limiting toxicity (DLT)

    Present the frequency and percentage of dose-limiting toxicity (DLT) occurrence across dose cohorts, along with detailed information on the types of DLTs.

    Time frame: Up to 14 weeks

  2. <Phase 1> Adverse drug reactions related to discontinuation of clinical trial drug administration

    Present the frequency and percentage of dose-limiting toxicity (DLT) occurrence across dose cohorts, along with detailed information on the types of DLTs.

    Time frame: Up to 14 weeks

  3. <Phase 2> Change in time to stand test (TTSTAND)

    Present the changes in time to stand test (TTSTAND) at the 48-week time point compared to baseline (Visit 2). Provide the subject count, mean, standard deviation, median, minimum, and maximum for the change in each treatment group. Analyze the change as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline TTSTAND values and age as fixed effects in the analysis.

    Time frame: At 48 weeks compared to baseline (Visit 2)

Secondary outcomes

  1. <Phase 1> Time to stand test (TTSTAND) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  2. <Phase 1> TTSTAND velocity (1/TTSTAND) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  3. <Phase 1> Time to run/walk 10 meters test (TTRW) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36,, and 48 weeks compared to baseline (Visit 2)

  4. <Phase 1> TTRW velocity (1/TTRW) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  5. <Phase 1> North Star Ambulatory Assessment (NSAA) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  6. <Phase 1> Time to climb 4 steps test (TTCLIMB) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  7. <Phase 1> TTCLIMB velocity (1/TTCLIMB) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  8. <Phase 1> 6-minute walk test (6MWT) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  9. <Phase 1> Changes amount in muscle strength by region

    The changes in shoulder abduction, elbow flexion/extension, knee flexion/extension, and handgrip are evaluated using hand-held myometry. (Unit: lbs) Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  10. <Phase 1> Changes amount in parameters related to pulmonary function

    Through spirometry testing, % predicted forced vital capacity (FVC%), forced vital capacity (FVC, unit L), forced expiratory volume in one second (FEV1), peak expiratory flow rate (PEFR), maximal inspiratory pressure (MIP), maximal expiratory pressure (MEP). Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 12, 24, and 48 weeks compared to baseline (Visit 2)

  11. <Phase 1> Changes amount in parameters related to cardiac function

    Through echocardiography, changes in left ventricular ejection fraction (LVEF), fractional shortening (FS), and left ventricular end-diastolic diameter (LVEDd) are evaluated. Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: At 48 weeks compared to screening (Visit 1)

  12. <Phase 1> Change rate of creatine kinase (CK) at each visit after administration of investigational product compared to baseline (Visit 2)

    Present the subject count, mean, standard deviation, median, minimum, and maximum for the changes at each time point within each dosage group.

    Time frame: From baseline

  13. <Phase 2> Time to stand test (TTSTAND) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, and 36 weeks compared to baseline (Visit 2)

  14. <Phase 2> TTSTAND velocity (1/TTSTAND) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  15. <Phase 2> Time to run/walk 10 meters test (TTRW) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  16. <Phase 2> TTRW velocity (1/TTRW) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  17. <Phase 2> North Star Ambulatory Assessment (NSAA) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  18. <Phase 2> Time to climb 4 steps test (TTCLIMB) change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  19. <Phase 2> TTCLIMB velocity (1/TTCLIMB) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  20. <Phase 2> 6-minute walk test (6MWT) change amount

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  21. <Phase 2> Changes amount in muscle strength by region

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 6, 12, 18, 24, 36, and 48 weeks compared to baseline (Visit 2)

  22. <Phase 2> Changes amount and rate of change in whole thigh muscle volume and index assessed by MRI

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 48 weeks compared to screening (Visit 1)

  23. <Phase 2> Changes amount in parameters related to pulmonary function

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 12, 24, and 48 weeks compared to baseline (Visit 2)

  24. <Phase 2> Changes amount in parameters related to cardiac function

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 48 weeks compared to screening (Visit 1)

  25. <Phase 2> Change rate of creatine kinase (CK) at each visit after administration of investigational product compared to baseline (Visit 2)

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: From baseline

  26. <Phase 2> Pediatric Outcomes Data Collection Instrument (PODCI) item score and total score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 24 and 48 weeks compared to baseline (Visit 2)

  27. <Phase 2> Pediatric Quality of Life inventory™ (PedsQL™) item scores and total score change

    Present the subject count, mean, standard deviation, median, minimum, and maximum for changes at each time point and for each dosage group. Analyze the change (or percentage change) as the dependent variable using a repeated measures mixed model (MMRM) with treatment group, visit (6, 12, 18, 24, 36, 48 weeks), and the interaction between treatment group and visit as factors. Include baseline (or screening) values of each assessment variable, age, and a stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as fixed effects in the analysis. However, for variables related to TTSTAND, do not include the stratification factor (TTSTAND ≤ 8 seconds / \> 8 seconds) as a fixed effect.

    Time frame: At 24 and 48 weeks compared to baseline (Visit 2)

  28. <Phase 1> Adverse Event

    After the application of the investigational medicinal product in the clinical trial, provide the number of subjects, incidence rate, and number of occurrences for adverse events, drug-related adverse events, serious adverse events, serious drug-related adverse events, adverse events related to discontinuation of the investigational medicinal product, drug-related adverse events related to discontinuation of the investigational medicinal product, and injection-related adverse events, categorized by dosage group. Additionally, code the occurrences by system organ class (SOC) and preferred term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA), and present the number of subjects, incidence rate, and number of occurrences for each dosage group according to SOC and PT.

    Time frame: Up to 48weeks. However, adverse drug reactions that persist at the end of the clinical trial will be followed up until the possible adverse reactions are resolved or it is determined that further follow-up is not meaningful.

  29. <Phase 1> Laboratory examination

    Number of participants with clinically significant abnormalities in Laboratory parameters after EN001 administration. Hematological tests, Blood chemical tests, Blood coagulation test, Urine test, Serum virus test It is conducted through blood and urine collection, and the PI checks whether the test results are normal, abnormal, and clinically significant.

    Time frame: Up to 48weeks. At Baseline and Week 4, tests are conducted before and within 4 hours after administration of the investigational drug, and PT INR and aPTT are performed only at the screening visit.

  30. <Phase 1> Vital sign

    Number of participants with clinically significant abnomalities in vital signs after EN001 administration. Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (℃) and will be assessed. For changes at each time point within each dosage group, present continuous variables with subject count, mean, standard deviation, median, minimum, and maximum. For categorical variables, provide frequency and percentage.

    Time frame: Up to 48weeks.

  31. <Phase 2> Adverse Event

    After the administration of the investigational product in the clinical trial, provide the number of subjects, incidence rate, and number of occurrences for adverse events, drug-related adverse events, serious adverse events, serious drug-related adverse events, adverse events related to discontinuation of the investigational product, drug-related adverse events related to discontinuation of the investigational product, and injection-related adverse events, categorized by treatment group. Additionally, code the occurrences by system organ class (SOC) and preferred term (PT) using the Medical Dictionary for Regulatory Activities (MedDRA), and present the number of subjects, incidence rate, and number of occurrences for each treatment group according to SOC and PT.

    Time frame: Up to 48weeks. However, adverse drug reactions that persist at the end of the clinical trial will be followed up until the possible adverse reactions are resolved or it is determined that further follow-up is not meaningful.

  32. <Phase 2> Laboratory examination

    Number of participants with clinically significant abnormalities in Laboratory parameters after EN001 administration. Hematological tests, Blood chemical tests, Blood coagulation test, Urine test, Serum virus test It is conducted through blood and urine collection, and the PI checks whether the test results are normal, abnormal, and clinically significant.

    Time frame: Up to 48weeks. At Baseline and Week 4, tests are conducted before and within 4 hours after administration of the investigational drug, and PT INR and aPTT are performed only at the screening visit.

  33. <Phase 2> Vital sign

    Number of participants with clinically significant abnomalities in vital signs after EN001 administration. Vital Signs include blood pressure (mmHg), pulse (times/minute), respiratory rate (times/minute), and body temperature (℃) and will be assessed. For changes at each time point within each treatment group, present continuous variables with subject count, mean, standard deviation, median, minimum, and maximum. For categorical variables, provide frequency and percentage.

    Time frame: Up to 48weeks.

07

Study locations

2 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Nov 2025, 20 months later.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Mar 25, 2024
StartEst.
Mar 2024
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06328725
Lead sponsor
ENCell
Responsible party
Sponsor
First posted
Mar 25, 2024
Start date
Mar 2024 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Mar 25, 2024

Study contacts

ENCell
Contact
encell@encellinc.com
82-2-6205-8054

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: EN001

Start the discussion